Ileal perforation at the site of peritoneal metastasis with intestinal infiltration by dual EGFR-VEGF pathway inhibition in an EGFR-mutant non-small cell lung cancer patient

Conflict of interest

Tatsuya YOSHIDA reports personal fees from Novartis, personal fees from AbbVie, personal fees from Amgen, personal fees from Daiichi-Sankyo, personal fees from AstraZeneca, personal fees from MSD, personal fees from Chugai, personal fees from Astellas, personal fees from Medpace, personal fees from Boehringer Ingelheim, personal fees from BMS, personal fees from Takeda, personal fees from Pfizer, personal fees from Lilly, personal fees from ONO, personal fees from Merck.

Yuichiro OHE reports personal fees from AstraZeneca, personal fees from Chugai, personal fees from Lilly, personal fees from ONO, personal fees from BMS, personal fees from Boehringer Ingelheim, personal fees from Bayer, personal fees from Pfizer, personal fees from MSD, personal fees from Taiho, personal fees from Nippon Kayaku, personal fees from Kyowa Hakko Kirin, personal fees from Eisai, personal fees from Daiichi-Sankyo.

Informed consent and patient details

The study participant provided informed consent, and the study design was approved by the appropriate ethics review board.

Comments (0)

No login
gif